Compugen Ltd.
As of Oct 22, 2026, Compugen is in Stage 3, the topping phase, now in week 2 (since Oct 12, 2026). It closed at $1.96, 36.8% below its 52-week high and below its 200-day average, which is rising.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CGEN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CGEN among Biotechnology150th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …150 | CGEN | Stage 3 · wk 2 | 63 | −16.2% |
Compugen: quick answers
What stage is Compugen in?
As of Oct 22, 2026, Compugen (CGEN) is in Stage 3, the topping phase. It entered Stage 3 on Oct 12, 2026 and is in week 2. What the four stages mean
Is Compugen in an uptrend?
Its uptrend has stalled. Compugen is in Stage 3, the topping phase that follows an advance. It trades 14.5% below its 200-day average, which is rising.
How far is Compugen from its 52-week high?
Compugen closed at $1.96 on Oct 22, 2026, 36.8% below its 52-week high of $3.10. Its 52-week low is $1.47.
How has Compugen performed over the past year?
As of Oct 22, 2026, Compugen is up 11.4% over the past year and up 26.5% so far in 2026.
Which sector and industry is Compugen in?
Compugen is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.